BMY Jan 2025 57.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.4600

0.0000

(0.00%)

As of 11:53AM EDT. Market open.

Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J., May 06, 2024--U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
PRINCETON, N.J., May 06, 2024--European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line....
Simply Wall St.
Bristol-Myers Squibb (NYSE:BMY) shareholders have endured a 33% loss from investing in the stock a year ago
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...